Key facts
- This page summarizes Simon Read's Form 3 filing for Dianthus Therapeutics, Inc. /DE/ (DNTH).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 22 May 2025, 16:39.
Simon Read - 22 May 2025 Form 3 Insider Report for Dianthus Therapeutics, Inc. /DE/ (DNTH)
- Reporting relationship
- Director
- Issuer ticker
- DNTH
- Reported as of
- 22 May 2025
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 22 May 2025, 16:39:18 UTC
- Next SEC filing
- 22 May 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Adam Veness, as attorney-in-fact for Simon Read
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Simon Read filed Form 3 for Dianthus Therapeutics, Inc. /DE/ (DNTH) on 22 May 2025.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0001688199
Primary reporting owner
Read Simon
- Relationship
- Director
- Address
- C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK
- Signature
- /s/ Adam Veness, as attorney-in-fact for Simon Read
- Signature date
- 22 May 2025
Additional SEC filing notes
Filing notes and footnotes
Ownership status
The filing reports no beneficially owned securities.
SEC remarks
Exhibit 24 - Power of Attorney